Optimizing Chemotherapeutic Anti-cancer Treatment and the Tumor Microenvironment: An Analysis of Mathematical Models.
暂无分享,去创建一个
[1] E Glatstein,et al. High-time chemotherapy or high time for low dose. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[2] H. Schättler,et al. Geometric Optimal Control , 2012 .
[3] H. Schättler,et al. Tumor Microenvironment and Anticancer Therapies: An Optimal Control Approach , 2014 .
[4] H. Schättler,et al. Dynamical properties of a minimally parameterized mathematical model for metronomic chemotherapy , 2016, Journal of mathematical biology.
[5] Gabriele Bergers,et al. Less is more, regularly: metronomic dosing of cytotoxic drugs can target tumor angiogenesis in mice. , 2000, The Journal of clinical investigation.
[6] P. Hahnfeldt,et al. Tumor development under angiogenic signaling: a dynamical theory of tumor growth, treatment response, and postvascular dormancy. , 1999, Cancer research.
[7] A. Perelson,et al. Nonlinear dynamics of immunogenic tumors: parameter estimation and global bifurcation analysis. , 1994, Bulletin of mathematical biology.
[8] Peter Bohlen,et al. Continuous low-dose therapy with vinblastine and VEGF receptor-2 antibody induces sustained tumor regression without overt toxicity , 2000 .
[9] H. Schättler,et al. On optimal delivery of combination therapy for tumors. , 2009, Mathematical biosciences.
[10] Avner Friedman,et al. Tumor cells proliferation and migration under the influence of their microenvironment. , 2011, Mathematical biosciences and engineering : MBE.
[11] H. Schättler,et al. Dynamics and control of a mathematical model for metronomic chemotherapy. , 2015, Mathematical biosciences and engineering : MBE.
[12] B. Perthame,et al. Populational adaptive evolution, chemotherapeutic resistance and multiple anti-cancer therapies , 2012, 1207.0923.
[13] Philip Hahnfeldt,et al. Maximum tolerated dose versus metronomic scheduling in the treatment of metastatic cancers. , 2013, Journal of theoretical biology.
[14] Urszula Ledzewicz,et al. A 3-Compartment Model for Chemotherapy of Heterogeneous Tumor Populations , 2015 .
[15] R. Kerbel. A cancer therapy resistant to resistance , 1997, Nature.
[16] Rakesh K. Jain,et al. Normalizing tumor vasculature with anti-angiogenic therapy: A new paradigm for combination therapy , 2001, Nature Medicine.
[17] U. Ledzewicz,et al. The influence of pk/pd on the structure of optimal controls in cancer chemotherapy models. , 2005, Mathematical biosciences and engineering : MBE.
[18] Kristian Pietras,et al. A multitargeted, metronomic, and maximum-tolerated dose "chemo-switch" regimen is antiangiogenic, producing objective responses and survival benefit in a mouse model of cancer. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[19] R. Kerbel. Tumor angiogenesis: past, present and the near future. , 2000, Carcinogenesis.
[20] Suzanne Lenhart,et al. Optimal control of treatment in a mathematical model of chronic myelogenous leukemia. , 2007, Mathematical biosciences.
[21] Urszula Ledzewicz,et al. OPTIMAL CONTROLS FOR A MATHEMATICAL MODEL OF TUMOR-IMMUNE INTERACTIONS UNDER TARGETED CHEMOTHERAPY WITH IMMUNE BOOST , 2013 .
[22] Urszula Ledzewicz,et al. Optimal Bang-Bang Controls for a Two-Compartment Model in Cancer Chemotherapy , 2002 .
[23] E. Glatstein,et al. Back to the basics: the importance of concentration x time in oncology. , 1993, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[24] J. Coldman. Drug resistance in cancer , 2016 .
[25] Urszula Ledzewicz,et al. OPTIMAL CONTROL FOR A CLASS OF COMPARTMENTAL MODELS IN CANCER CHEMOTHERAPY , 2003 .
[26] Olivier Fercoq,et al. Optimisation of Cancer Drug Treatments Using Cell Population Dynamics , 2013 .
[27] Urszula Ledzewicz,et al. Optimal response to chemotherapy for a mathematical model of tumor–immune dynamics , 2012, Journal of mathematical biology.
[28] Harvey Thomas Banks,et al. Preface. Distributed Parameter Systems in Immunology , 2012 .
[29] Nicolas André,et al. Metronomic chemotherapy: new rationale for new directions , 2010, Nature Reviews Clinical Oncology.
[30] K. Nan,et al. New insights into metronomic chemotherapy-induced immunoregulation. , 2014, Cancer letters.
[31] Helen Moore,et al. A mathematical model for chronic myelogenous leukemia (CML) and T cell interaction. , 2004, Journal of theoretical biology.
[32] Urszula Ledzewicz,et al. AntiAngiogenic Therapy in Cancer Treatment as an Optimal Control Problem , 2007, SIAM J. Control. Optim..
[33] Urszula Ledzewicz,et al. On the MTD paradigm and optimal control for multi-drug cancer chemotherapy. , 2013, Mathematical biosciences and engineering : MBE.
[34] Jaroslaw Smieja,et al. Cell Cycle as an Object of Control , 1995 .
[35] R. Gatenby. A change of strategy in the war on cancer , 2009, Nature.
[36] Urszula Ledzewicz,et al. ON OPTIMAL CHEMOTHERAPY FOR HETEROGENEOUS TUMORS , 2014 .
[37] Quanxu Ge,et al. CURVATURE-BASED CORRECTION ALGORITHM FOR AUTOMATIC LUNG SEGMENTATION ON CHEST CT IMAGES , 2014 .
[38] Urszula Ledzewicz,et al. Optimal Control for Mathematical Models of Cancer Therapies: An Application of Geometric Methods , 2015 .
[39] A. Friedman. Cancer as Multifaceted Disease , 2012 .
[40] Nicolas André,et al. Metronomic scheduling of anticancer treatment: the next generation of multitarget therapy? , 2011, Future oncology.
[41] L. Norton,et al. The Norton-Simon hypothesis revisited. , 1986, Cancer treatment reports.
[42] B. Perthame,et al. Modeling the Effects of Space Structure and Combination Therapies on Phenotypic Heterogeneity and Drug Resistance in Solid Tumors , 2014, Bulletin of Mathematical Biology.